Clinical trials: Platinum Resistant Ovarian Cancer
Epithelial Ovarian Cancer
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle.
- Trial name
- NCT00408603
- Testing
- Voreloxin Injection
- Where
- 20 sites in United States, Canada
- Volunteers
- 183 people
- Sponsor
- Sunesis Pharmaceuticals
Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian…
- Conditions
- Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07591831
- Testing
- Liposomal Irinotecan
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ovarian Cancer
Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer
Study of Pazopanib and weekly Paclitaxel in patients with platinum resistant/refractory ovarian cancer who relapse during bevacizumab maintenance.
- Trial name
- TAPAZ (NCT02383251)
- Testing
- Pazopanib, Paclitaxel
- Where
- 36 sites in France
- Volunteers
- 118 people
- Sponsor
- ARCAGY/ GINECO GROUP
Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer.
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Malignant Tumor of Peritoneum, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT01494012
- Testing
- stereotactic body radiation therapy, positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Ovarian Cancer, Fallopian Tube Cancer
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT00262990
- Testing
- EPO906 (Patupilone), doxorubicin
- Where
- 149 sites in United States, Australia and 10 more
- Volunteers
- 829 people
- Sponsor
- Novartis Pharmaceuticals
Platinum-resistant Ovarian Cancer, Recurrent Ovarian Cancer
H.O.P.E: Helping Ovarian Cancer Patients Cope
The purpose of this study is to test the effect of the gynecologic oncologists with palliative care specialist collaboration (GO-PC) intervention on patient quality of life.
- Conditions
- Platinum-resistant Ovarian Cancer, Recurrent Ovarian Cancer, Palliative Care
- Trial name
- NCT02090582
- Testing
- Structured Palliative Care, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Duke University
Ovarian Cancer
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
This clinical trial shall clarify the efficacy and safety of pazopanib in combination with weekly topotecan in patients with platinum-resistant or intermediate platinum-sensitive recurrent epithelial ovarian cancer, fallopian and…
- Trial name
- NCT01600573
- Testing
- pazopanib in combination with weekly topotecan
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- JSehouli
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03907527
- Testing
- PRGN-3005 UltraCAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Precigen, Inc
Ovarian Neoplasms, Peritoneal Neoplasms
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian…
- Trial name
- NCT07273396
- Testing
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel
- Volunteers
- 53 people
- Sponsor
- Seoul National University Hospital
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma
- Trial name
- NCT02650986
- Testing
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Cancer
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer.
- Trial name
- NCT01684878
- Testing
- Gemcitabine (Chemotherapy), Paclitaxel (Chemotherapy), Pertuzumab
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial investigates the effect of irinotecan liposome and bevacizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that shows less response to platinum therapy (platinum resistant)…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT04753216
- Testing
- Bevacizumab, Irinotecan Sucrosofate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03776812
- Testing
- Relacorilant, Nab-paclitaxel
- Where
- 24 sites in United States, Belgium and 3 more
- Volunteers
- 178 people
- Sponsor
- Corcept Therapeutics
Brenner Tumor, Fallopian Tube Cancer
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
RATIONALE: Colony stimulating factors, such as sargramostim (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing and may also increase the number of immune cells found in bone marrow or…
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
- Trial name
- NCT00466960
- Testing
- sargramostim, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Ovarian Neoplasms, Primary Peritoneal Cancer
Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy
The purposes of this study are to determine: - whether standard or higher doses of pemetrexed should be given to patients with ovarian or primary peritoneal cancer that has recurred; - the safety and side effects of standard and…
- Trial name
- NCT00109096
- Testing
- Pemetrexed
- Where
- 21 sites in Belgium, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Carcinoma, Ovarian Epithelial
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation…
- Conditions
- Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
- Trial name
- NCT05116189
- Testing
- Pembrolizumab, Paclitaxel, Bevacizumab
- Where
- 187 sites in United States, Australia and 23 more
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Platinum-resistant Epithelial Ovarian Cancer
A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer
This is a phase I/II study to find the highest dose of hydroxychloroquine that can be given safely with itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer.
- Trial name
- NCT03081702
- Testing
- Hydroxychloroquine, Itraconazole
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well Avatar-directed chemotherapy works in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that does not respond to platinum anti-cancer drugs.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02312245
- Testing
- Bevacizumab, Gemcitabine Hydrochloride, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Fallopian Tube Cancer, Ovarian Cancer
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00091377
- Testing
- cisplatin, paclitaxel, phenoxodiol
- Where
- 2 sites in United States, Australia
- Volunteers
- 65 people
- Sponsor
- MEI Pharma, Inc.
Recurrent, Platinum-resistant
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating…
- Conditions
- Recurrent, Platinum-resistant, High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT01883297
- Testing
- Re-stimulated tumor-infiltrating lymphocytes (TILs), Interleukin-2, Cyclophosphamide
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University Health Network, Toronto